|
Exploratory Development
(Post discovery through Phase II) |
Full Development (Registrational program) |
Marketed Product Development (Approved in at least one major market) |
| EGFR/IGFR Tandem Adnectin (oncology) |
Brivanib (oncology) |
YERVOY™ (ipilimumab)
(oncology) |
Pegdinetanib
(VEGF R-2 Adnectin) (oncology) |
Elotuzumab (oncology) |
SPRYCEL® (dasatinib)
(oncology) |
| Anti-CD70 ADC (oncology) |
Necitumumab (oncology) |
ERBITUX® (cetuximab)
(oncology) |
| JAK2 Inhibitor (oncology) |
Dapagliflozin (metabolics) |
IXEMPRA® (ixabepilone) (oncology) |
| IGF-1R Antagonist (oncology) |
Apixaban (cardiovascular) |
ONGLYZA® (saxagliptin) KOMBIGLYZE XR™ (saxagliptin and metformin HCL extended-release) (metabolics) |
| SMO Antagonist (oncology) |
Daclatasvir (NS5A inhibitor)(virology) |
NULOJIX®(belatacept) (immunology) |
| IL-21 (oncology) |
|
ORENCIA® (abatacept) (immunology) |
| Anti-KIR (oncology) |
|
BARACLUDE® (entecavir) (virology) |
| Urelumab (Anti-CD137) (oncology) |
|
REYATAZ® (atazanavir sulfate) (virology) |
| Notch Inhibitors (oncology) |
|
SUSTIVA® (efavirenz) ATRIPLA® (efavirenz / emtricitabine / tenofovir disoproxil fumarate) (virology) |
| Anti-PD1 (oncology) |
|
ABILIFY® (neuroscience) |
| Anti-CXCR4 (oncology) |
|
|
| Anti-LAG3 (oncology) |
|
|
| PEG-FGF21 (metabolics) |
|
|
| 11βHSD Inhibitors (metabolics) |
|
|
| TGR5 agonist (metabolics) |
|
|
| FGF21-PKE Adnectin (metabolics) |
|
|
| GPR119 Agonists (metabolics) |
|
|
| CCR1 Antagonists (immunology) |
|
|
| Anti-IP10 (immunology) |
|
|
| Anti-CD28 (immunology) |
|
|
| Anti-IL6 (immunology) |
|
|
| IL-23 Adnectin (immunology) |
|
|
| Anti-IL31 (immunology) |
|
|
| Anti-CD40L (immunology) |
|
|
| LPA1 Antagonist (immunology) |
|
|
| LXR Modulators (cardiovascular) |
|
|
| PCSK9 Adnectin (cardiovascular) |
|
|
| CCR2 / 5 Antagonists(cardiovascular) |
|
|
| IKACh Inhibitors (cardiovascular) |
|
|
| IKur Antagonists(cardiovascular) |
|
|
| Peginterferon lambda-1a (virology) |
|
|
| Asunaprevir (NS3 Inhibitor) (virology) |
|
|
| NS5B Inhibitor (virology) |
|
|
| HIV Attachment Inhibitor (virology) |
|
|
| Anti-PD-L1 (virology) |
|
|
| NRT Inhibitor (virology) |
|
|
| HIV Maturation Inhibitor (virology) |
|
|
| NS5B Primer Grip Inhibitor (virology) |
|
|
| NS5A Second Generation (virology) |
|
|
| NS5B Site 1 Inhibitor (virology) |
|
|
| α-7 Nicotinic Agonist (neuroscience) |
|
|
| Aβ Modulator (neuroscience) |
|
|
| Triple Reuptake Inhibitors (neuroscience) |
|
|
| Microtubule Stabilizer (neuroscience) |
|
|
| Avagacestat (Gamma Secretase Inhibitor) (neuroscience) |
|
|
| GABA/Nicotinic Modulator (neuroscience) |
|
|
| CGRP Antagonist (neuroscience) |
|
|
|
|
|
|